Results 21 to 30 of about 31,861 (267)

Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. [PDF]

open access: yesPLoS ONE, 2013
IL-1 receptor antagonist anakinra is usually highly efficient in Schnitzler syndrome (SS), a rare inflammatory condition associating urticaria, fever, and IgM monoclonal gammopathy.
David Launay   +9 more
doaj   +1 more source

Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) [PDF]

open access: yes, 2017
Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of con-firmed HF cases in the United States. However, there are no highly effective evidence-basedtreatments currently available for these patients.
Abbate, Antonio   +10 more
core   +1 more source

Anakinra Therapy for Non-cancer Inflammatory Diseases

open access: yesFrontiers in Pharmacology, 2018
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-
Giulio Cavalli   +3 more
doaj   +1 more source

Severe osteoarticular involvement in isotretinoin-triggered acne fulminans: two cases successfully treated with anakinra. [PDF]

open access: yes, 2017
Acne fulminans (AF) is a severe form of inflammatory and ulcerated acne associated with fever, malaise, joint swellings and polyarthralgia.1 Osteoarticular lesions are often described and can be radiologically indistinguishable from those observed in
Barbareschi   +9 more
core   +1 more source

Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature [PDF]

open access: yes, 2015
Macrophage activation syndrome (MAS) is a potentially fatal condition. It is a rare complication of several autoimmune disorders, including systemic lupus erythematosus (SLE) and systemic juvenile idiopathic arthritis (sJIA).
Didona, Dario   +4 more
core   +4 more sources

Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

open access: yesGlobal & Regional Health Technology Assessment, 2020
Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and ...
Roberto Ravasio   +2 more
doaj   +1 more source

Candida albicans colonization and dissemination from the murine gastrointestinal tract : the influence of morphology and Th17 immunity [PDF]

open access: yes, 2014
This article is protected by copyright. All rights reserved. This work was supported by the Wellcome Trust (086558, 080088, 102705), a Wellcome Trust Strategic Award (097377) and a studentship from the University of Aberdeen. D.K.
Brown, Alistair J P   +9 more
core   +1 more source

Anakinra reduces lung inflammation in experimental acute lung injury

open access: yesImmunity, Inflammation and Disease, 2022
Introduction Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury (ALI) resulting in life‐threatening hypoxaemia. Although ARDS can be caused by a variety of pathogens or major trauma, it is best known as the major cause of ...
Paul Engeroff   +3 more
doaj   +1 more source

Protective effect of anakinra on audiovestibular function in a murine model of endolymphatic hydrops

open access: yesFrontiers in Cellular Neuroscience, 2022
IntroductionMénière’s disease (MD), a common disease in the inner ear, is characterized by an increase in endolymph in the cochlear duct and vestibular labyrinth. The pathophysiology of the condition appears to be the immune response.
Na Zhang   +41 more
doaj   +1 more source

Molecular Predictors of Anakinra Treatment Success in Heart Failure Patients with Reduced Ejection Fraction [PDF]

open access: yes, 2020
Background. Kineret (Anakinra) is an interleukin-1 antagonist that is under investigation for its novel clinical application treating patients that have heart failure with reduced (\u3c50%) ejection fraction (HFrEF).
Abbate, Antonio   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy